The effect of a cinnamon-, chromium- and magnesium-formulated honey on glycaemic control, weight loss and lipid parameters in type 2 diabetes: an open-label cross-over randomised controlled trial
- 1.4k Downloads
This randomised controlled trial assessed the acute and long-term effects of daily supplementation of kanuka honey, formulated with cinnamon, chromium and magnesium on glucose metabolism, weight and lipid parameters in individuals with type 2 diabetes.
Twelve individuals with type 2 diabetes received 53.5 g of a formulated honey and a control (non-formulated) kanuka honey in a random order for 40 days, using cross-over design. Fasting glucose, insulin, HbA1c, lipids and anthropometric measures were measured at baseline and end of treatment. A meal tolerance test was performed at baseline to assess acute metabolic response.
There was no statistically significant difference in acute glucose metabolism between treatment groups, as measured by the Matsuda index and AUC for glucose and insulin. After the 40-day intervention with honey, fasting glucose did not differ significantly between the two treatments (95 % CI −2.6 to 0.07). There was no statistically significant change in HbA1c or fasting insulin. There was a statistically significant reduction in total cholesterol by −0.29 mmol/L (95 % CI −0.57 to −0.23), LDL cholesterol by −0.29 mmol/L (95 % CI −0.57 to −0.23) and weight by −2.2 kg (95 % CI −4.2 to −0.1). There was a trend towards increased HDL and reduced systolic blood pressure in the intervention treatment.
The addition of cinnamon, chromium and magnesium supplementation to kanuka honey was not associated with a significant improvement in glucose metabolism or glycaemic control in individuals with type 2 diabetes. Use of the formulated honey was associated with a reduction in weight and improvements in lipid parameters, and should be investigated further.
KeywordsDiabetes Honey Cinnamon Chromium Magnesium Lipids
Conflict of interest
The honey products and study funding were provided by Honeylab Ltd. The authors have no financial interest in this company, and the company had no influence on the reporting of results. The authors declare that they have no conflict of interest.
This study was approved by the Ministry of Health Central Regional Ethics Committee (13/CEN/91) and was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12613000624785). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants gave written informed consent prior to their inclusion in the study.
- 1.The Holy Qur'an. Surat An-Nahl [16:69]. http://quran.com/16/69. Accessed 15 Oct 2014
- 5.Erejuwa OO, Sulaiman SA, Ab Wahab MS et al (2001) Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. Int J Biol Sci 7:244–252Google Scholar
- 15.Grant AP, McMullen JK (1982) The effect of brewer’s yeast containing glucose tolerance factor on the response to treatment in type 2 diabetics: a short controlled study. Ulster Med J 51:110–114Google Scholar
- 16.Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA (2000) The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with Type 2 diabetes. Saudi Med J 21:831–837Google Scholar
- 19.Uusitupa MI, Kumpulainen JT, Voutilainen E et al (1983) Effect of inorganic chromium supplementation on glucose tolerance, insulin response and serum lipids in noninsulin-dependent diabetics. Am J Clin Nutr 38:404–410Google Scholar
- 30.Jeejeebhoy KN, Chu RC, Marliss EB et al (1977) Chromium deficiency, glucose intolerance and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 30:531–538Google Scholar
- 32.Abdollahi M, Farshchi A, Nikfar S, Seyedifar M (2013) Effect of chromium on glucose and lipid profiles in patients with Type 2 diabetes; A meta-analysis review of randomized trials. J Pharm Pharm Sci 16:99–114Google Scholar
- 36.Letinsky D, Kelsberg G (2011) Is cinnamon safe and effective for treating lipid disorders? J Fam Pract 60:43–44Google Scholar
- 41.Hlebowicz J, Darwiche G, Björgell O, Almér L-O (2007) Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr 85:1552–1556Google Scholar